Prevention of post-contrast kidney injury in patients with cancer.

Autor: Grassedonio E; Biomedicine Department, Neuroscience and Advance Diagnostics, University of Palermo, Palermo, Italy., Incorvaia L; Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Palermo, Italy., Guarneri M; Nephrology and Dialysis, Azienda Ospedaliera Universitaria 'Paolo Giaccone' Polyclinic, Palermo, Italy., Guagnini F; GE HealthCare Pharmaceutical Diagnostic (PDx), Milan, Italy., Midiri M; Biomedicine Department, Neuroscience and Advance Diagnostics, University of Palermo, Palermo, Italy.
Jazyk: angličtina
Zdroj: Drugs in context [Drugs Context] 2024 Mar 14; Vol. 13. Date of Electronic Publication: 2024 Mar 14 (Print Publication: 2024).
DOI: 10.7573/dic.2023-11-2
Abstrakt: Post-contrast acute kidney injury is defined as a nephropathy with an increase in serum creatinine of >0.3 mg/dL (or >26.5 μmol/L) or >1.5-times the baseline within 48-72 h of intravascular administration of a contrast medium. Patients with cancer have an increased risk of post-contrast acute kidney injury not only related to the frequent use of contrast medium for computed tomography scans but also to other factors, including the type of tumour, age, oncological therapies, use of other nephrotoxic agents and dehydration. Preventive strategies were developed and may be applied to different risk profiles. Patients at risk may be detected by recently published risk scores.
Competing Interests: Disclosure and potential conflicts of interest: FG is an employee of GE HealthCare, Pharmaceutical Diagnostics (PDx), Milan, Italy. The other authors have no conflicts to declare. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2024/02/dic.2023-11-2-COI.pdf
(Copyright © 2024 Grassedonio E, Incorvaia L, Guarneri M, Guagnini F, Midiri M.)
Databáze: MEDLINE